In 2014, we started to study breast cancer, specifically the Her2 Kinase, which is a part of the EGFR family of Tyrosine kinases, responsible for initiating a host of biochemical pathways. These kinases are critical for regulating cell division and thus mutations within the EGFR family have been linked to various types of cancers, including breast and pancreatic cancer.
The aim of projects 9104 to 9114 is to understand the effect of certain mutations in the kinase domain of Her2. We are also hoping to find new druggable states within the system for creating the next generation of targeted cancer therapeutics, as well as to study the effect of mutations, which will give us insight into mutations present in breast cancer tumors.
Understanding epigenetic cancer targets with Folding@home: Histone methyltransferases NSD1, NSD2, and NSD3
The Chodera Lab at the Memorial Sloan Kettering Cancer Center is now running a series of projects to study the conformational dynamics of histone methyltransferases to aid in the rational design of new small molecule…Read more
Fighting cancer on Folding@home: FDA approved kinase inhibitors
You may have noticed a trend in the type of proteins being simulated on Folding@home recently. A number of Folding@home labs are collaborating in an attempt to understand the role…Read more
Breast Cancer and Her2 Kinase: Projects 9104-9114
We are continuing to make a big push into studying cancer. Next up, is work relevant for breast cancer. Specifically, we have started to study the Her2 Kinase, a part…Read more
New projects to help design selective inhibitors of protein methyltransferases
The Chodera lab has teamed up with Luo lab at MSKCC to study another important class of cancer targets: protein methyltransferases. These are protein-modifying enzymes that catalyze the transfer of…Read more
Fighting cancer on Folding@Home: EGFR
[Guest post by Daniel L. Parton of the Chodera Lab, Memorial Sloan-Kettering Cancer Center.] We’re about to roll out our first major F@h project on the new work server at…Read more